Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

43 questions · 57 findings · 11 reviews · Oral Health · related questions CL0289

No studies found 11 · 19.3%GRADE not reported 26 · 45.6%Very low 16 · 28.1%Low 0 · 0%Moderate 2 · 3.5%High 2 · 3.5%

Topical thalidomide vs Another topical agent or placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers

The review found no eligible studies for this question.

1 finding from 1 review
  • No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6…
    0 studies
    No studies found

Topical corticosteroids vs Another topical agent or placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers

The review found no eligible studies for this question.

1 finding from 1 review
  • No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6…
    0 studies
    No studies found

HAART regimen + topical treatment vs HAART alone

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers

The review found no eligible studies for this question.

1 finding from 1 review
  • No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6…
    0 studies
    No studies found

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

Relief of pain · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Aciclovir (oral or intravenous) for treatment vs placebo

Relief of pain · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Relief of pain · Patients with cancer receiving chemotherapy and/or radiotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Neocone vs Alvogyl

Time to initial pain relief (minutes) · Adults (>18 years) with established dry socket following permanent tooth extraction

Neocone led to higher time to initial pain relief (minutes) compared with alvogyl; GRADE not reported.

1 finding from 1 review

Topical treatments (benzydamine hydrochloride oral rinse) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · benzydamine hydrochloride
    SoF9 Topical treatments vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated topical treatment; 150 participants (4 RCTs); very low. Subgroups: benzydamine (1…
    4 studies · 150 participants
    Very low

Benzodiazepines (topical clonazepam) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

2 findings from 1 review

Anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clonazepam 0.5 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Cholinergics (bethanechol 15 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether cholinergics (bethanechol 15 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Psychological therapies (cognitive therapy) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether psychological therapies (cognitive therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Topical treatments (capsaicin oral rinse) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
2 findings from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · capsaicin oral rinse
    Capsaicin oral rinse (Marino 2010; Silvestre 2012) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory). Silvestre 2012 data not presented due to 23% first-phase…
    1 study
    GRADE not reported
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    long-term (>3 to 6 months) · capsaicin oral rinse
    MD -2.60 [-5.11, -0.09]
    1 study · 18 participants
    Very low

Amisulpride (antipsychotic, 50 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months)
    Bogetto 1999 (amisulpride) included in the antidepressants/antipsychotics comparison but data not presented due to excessive attrition (19/24; 79%) in the placebo arm.
    1 study
    GRADE not reported

Antidepressants (trazodone 200 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clordemetildiazepam 1 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · clordemetildiazepam
    Bogetto 1999 (clordemetildiazepam) included in the benzodiazepine comparison but data not presented (79% placebo-arm attrition).
    1 study
    GRADE not reported